The capital of the UAE has announced another “anchor” project in the healthcare sector: M42ClevelandClinic AbuDhabi, together with Toshiba Energy Systems &Solutions, will build the first heavy-ion therapy center in the Middle East. This is a facility that accelerates carbon ions to 70% of the speed of light and “hits” tumors with precision, minimizing damage to healthy tissue. There are only 15 such complexes operating in the world, and none are located within a five-hour flight radius of Abu Dhabi — therefore, the emirate claims the status of a regional hub for advanced oncology, Bloomberg has reported.
Construction will start in 2026, and the launch is scheduled for early 2029. The project is part of a broader multi-billion dollar program of economic diversification, where healthcare is identified as a priority along with energy and technology. DubaiChamber estimates that the GCC healthcare market will be worth $135 billion by 2030, and Abu Dhabi is aiming to capture a lion’s share of this pie by offering world-class infrastructure and generous incentives for private investors.
M42: An AI ecosystem funded by Mubadala and G42
The M42 platform was launched in 2023 when AI holding company G42 and sovereign wealth fund Mubadala Investment Co. ($330 billion AUM) consolidated their healthcare assets. Since then, the company has made a number of deals: the purchase of Swedish-Spanish dialysis clinic chain Diaverum has catapulted M42 into the top 5 private nephrology providers globally. According to CEO Hassan Jasem Al-Nowais, there are “dozens of M&A targets” in the pipeline, from telemedicine to pharmaceutical R&D, all of which will be integrated through the holding’s AI core.
Strategic alliances already include Illumina Inc.: the partners are developing algorithms for rapid genome sequencing and interpretation, which will become the basis of precision medicine in the emirate. M42 also administers the Emirati Genome Program, which accumulates big-data profiles of citizens to create models for predicting chronic diseases and personalized treatment regimens. The heavy-ion center will be another node in this ecosystem, providing clinical trials and data for the AI platform.
Why healthcare is the new vector of capital for the UAE
Over the past five years, Emirati investors have invested more than $10 billion in international healthcare assets. This year alone, PureHealth HoldingPJSC acquired a Greek hospital chain from CVC Capital for $2.3 billion, underscoring Abu Dhabi’s ambitions to build a global portfolio. Locally, the heavy-ion project has had a multiplier effect: creating highly skilled jobs, developing related industries (radiology equipment, isotopes, medical logistics) and reducing medical tourism abroad, which used to “drain” the country of hundreds of millions of dollars every year.
EY experts estimate the potential savings in government spending on oncology treatment abroad at $150–200 million per year after the center is launched. Add to this the possible revenues from patients from neighboring GCC and South Asian countries, and the financial logic of the project becomes obvious. From an investor’s perspective, Abu Dhabi is turning into a rare combination: deep capital reserves, a favorable regulatory environment and an ambition to create medical technologies that have not yet been seen in the region.